Prognostic Significance of Prostate-Specific Antigen Levels Two Months after Hormonal Manipulation of Metastatic Prostate Cancer

1997 ◽  
Vol 32 (1) ◽  
pp. 58-63 ◽  
Author(s):  
S. (a) Kawakami ◽  
K. (a) Takagi ◽  
T. (b) Ueda ◽  
I. (b) Fukui ◽  
T. (b) Kawai
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Metastatic Prostate Cancer ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Hormonal Manipulation

Detectable Prostate Specific Antigen Between 60 and 120 Days Following Radical Prostatectomy for Prostate Cancer: Natural History and Prognostic Significance

2006 ◽  
Vol 176 (2) ◽  
pp. 559-563 ◽  
Author(s):  
Shomik Sengupta ◽  
Carl M. Christensen ◽  
Horst Zincke ◽  
Jeffrey M. Slezak ◽  
Bradley C. Leibovich ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Natural History ◽  
Prostate Specific Antigen ◽  
Prognostic Significance ◽  
Specific Antigen

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 ◽  
Vol 11 (4) ◽  
pp. 607-615 ◽  
Author(s):  
W K Kelly ◽  
H I Scher ◽  
M Mazumdar ◽  
V Vlamis ◽  
M Schwartz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Specific Antigen ◽  
Phase Iii ◽  
Cancer Center ◽  
Hormone Refractory Prostate Cancer ◽  
Data Set ◽  
Hormone Refractory

PURPOSE To evaluate the prognostic significance of pretreatment parameters and posttherapy declines in prostate-specific antigen (PSA) in relation to the survival of patients with hormone-refractory prostate cancer. PATIENTS AND METHODS One hundred ten assessable patients treated on seven sequential protocols at Memorial Sloan-Kettering Cancer Center (MSKCC) for hormone-refractory prostate cancer were evaluated for 29 different pretherapy and posttherapy parameters, including a posttherapy decline in PSA of 50% and 80% from baseline. RESULTS In the univariate analysis, initial Karnofsky performance status (KPS) > or = 80% was associated with a favorable outcome (P = .005), while age, extent of disease on bone scan, and individual sites of metastatic disease were not significant. No difference in survival was observed between patients with measurable or assessable (bone only) disease. Initial hemoglobin (HGB; P = .0012), alkaline phosphatase (ALK; P = .0015), and lactate dehydrogenase (LDH; P = .0002) levels were significant discriminators, while the initial PSA was not. Using a landmark analysis, a significantly longer median survival rate was observed for patients with a > or = 50% decline in PSA (median not reached) versus patients with a less than 50% decline in PSA (median, 8.6 months; P = .0001). Multivariate analysis using the Cox proportional hazards model showed that a > or = 50% decline in PSA (P = .0004) and the natural log of LDH (P = .0001) were the two most significant variables predicting survival. The model was confirmed on an independent data set from the Norwegian Radium Hospital (NRH) in Oslo, Norway. CONCLUSION The results suggest that posttherapy PSA declines can be used as a surrogate end point to evaluate new agents in hormone-refractory prostate cancer. The criteria for response need prospective validation in phase III trials.

Clinical Protocol: Phase I Study of an Adenovirus/Prostate-Specific Antigen Vaccine in Men with Metastatic Prostate Cancer

2006 ◽  
Vol 0 (0) ◽  
pp. 060123080936010
Author(s):  
David M. Lubaroff ◽  
Badrinath Konety ◽  
Brian K. Link ◽  
Timothy L. Link ◽  
Tammy Madsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Prostate Specific Antigen ◽  
Phase I Study ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Clinical Protocol ◽  
Antigen Vaccine

Response of Prostate-Specific Antigen after Androgen Withdrawal and Prognosis in Men with Metastatic Prostate Cancer

1998 ◽  
Vol 60 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Yuzo Furuya ◽  
Susumu Akimoto ◽  
Koichiro Akakura ◽  
Tatsuo Igarashi ◽  
Shino Murakami ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Metastatic Prostate Cancer ◽  
Specific Antigen ◽  
Androgen Withdrawal
Sign in / Sign up

Export Citation Format

Share Document